Foreword; Preface; Contents; Contributors; Part I: Cardiovascular Disease (CVD) in Chronic Kidney Disease (CKD): Same or Different?; 1: Epicardial Coronary Heart Disease in CKD: Diagnosis and Management; Chronic Kidney Disease (CKD) and Coronary Heart Disease: General Considerations; Clinical Evaluation of Coronary Heart Disease in CKD; Coronary Angiography; Contrast-Induced Acute Kidney Injury (CI-AKI); Risk of Bleeding; Anemia; Technique; Type of Stent; Other Peri-procedural Complications; Surgical Intervention; Medical Treatment; Aspirin; Clopidogrel; Prasugrel; Ticagrelor

Unfractionated Heparin and Low Molecular Weight Heparin Glycoprotein IIb/IIIa Inhibitors; Bivalirudin; Beta-Blockers; Statins; Renin-Angiotensin-Aldosterone System Blockers; Nitrates; Control of Other Risk Factors; Special Considerations for Evaluating Patients Prior to Renal Transplantation; Summary and Conclusions; References; 2: Small Vessel Disease in CKD, Diabetes, Obesity and Hypertension; What Has Occurred in This gentleman's Kidneys over the Antecedent Years, and How Could This Have Been Prevented?

Small Artery Function and Dysfunction: Remodelling, Myogenic Tone and the EndotheliumEndothelial Dependent Mechanisms; Glomerular Endothelial Changes in Diabetes; Retinal Microvasculature and Cardiovascular Risk; Inflammation and Perivascular Adipose Tissue; "What Importance Does This Have for Our Patient in Clinic? And What Further Advice Can We Offer?"; References; 3: Sudden Cardiac Death and Arrhythmia in CKD; Introduction; Risk Factors and Mechanisms; Coronary Artery Disease; Arteriosclerosis and Arterial Calcification; Microvessel Disease; Cardiomyopathy and Cardiac Fibrosis

Sympathetic Overactivity Inflammation; Abnormalities in Mineral Metabolism; Electrolyte Shifts and Hypervolemia; QT Prolongation; Evidence for Best Management; Beta-Adrenergic Blockers; Renin-Angiotensin System (RAS) Blockade; Dialysis Dose and Avoiding low Potassium Dialysate; Management of Mineral Abnormalities; Implantable Cardiac Defibrillator; Provision of Healthcare; Conclusion; References; 4: Anticoagulation in CKD; Indications for Anticoagulation in Chronic Kidney Disease; Stroke Risk in Patients with Chronic Kidney Disease; Determining the Risk of Stroke

Warfarin in Patients with Chronic Kidney Disease Direct-Acting Oral Anticoagulants (DOACs) in Chronic Kidney Disease; Dabigatran; Rivaroxaban; Apixaban; Edoxaban; Low Molecular Weight Heparins in Chronic Kidney Disease; Anticoagulation for Patients with Atrial Fibrillation on Peritoneal Dialysis; Anticoagulation for Atrial Fibrillation in Renal Transplant Patients; Assessing Risk of Bleeding in Patients with Chronic Kidney Disease; Conclusions; References; 5: MRA Inhibition in CKD: More Than Salt and Water; Introduction; Aldosterone